GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Evonile Pharma Ltd

Evonile Pharma Board Approves Q2 FY27 Unaudited Financial Results

RESULTS ● No Immediate Change LOW RISK
📅 Filed on BSE: 03 Nov 2026, 07:04 PM IST  ·  BSE ID: e95b6b45-206f-4e45-810a-9dbc57669917
View Original BSE Filing (PDF)
💡
In Simple Terms
Evonile Pharma's board approved its financial results for the quarter and half-year ending September 30, 2026.
🤖 AI Summary
  • Evonile Pharma Board approved Unaudited Financial Results for Q2 FY27 and half year ended September 30, 2026.
  • The results were recommended by the Audit Committee and approved on November 03, 2026.
  • Limited Review Report from Statutory Auditors for the unaudited results was also taken on record.
  • The Board meeting commenced at 06:06 P.M. (IST) and concluded at 06:26 P.M. (IST).
👥 What This Means For Shareholders
✅
Action Required
No specific action is required from shareholders based on this approval announcement.
👤
Who Is Affected
All shareholders are affected as the company has fulfilled its regulatory obligation to announce its financial performance for Q2 FY27.
🔍
Management Signal
Management is adhering to regulatory timelines by disclosing its Q2 FY27 financial results and related review reports.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Review the detailed Q2 FY27 financial results for performance metrics.
Monitor future financial results for full fiscal year performance.
Watch for any further announcements regarding operational developments.
LOW RISK The filing is a routine regulatory compliance announcement of financial results.
💡 Investor Takeaway
Evonile Pharma Limited's Board of Directors considered and approved the Unaudited Financial Results for the quarter and half year ended September 30, 2026, along with the Limited Review Report from statutory auditors on November 03, 2026.
📅 Company Track Record
Evonile Pharma Limited was formerly known as Novartis India Limited. Past filings indicate the company reported Q2 FY27 revenue of ₹56.1 crore and Operating EBITDA of -₹31.8 crore in a November 3, 2026, press release. Total financial indebtedness for Q2 FY27 was reported as INR 800.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What financial period do the approved results for Evonile Pharma cover?
The approved unaudited financial results cover the quarter and half year ended September 30, 2026, which is Q2 FY27.
When did Evonile Pharma's Board approve these financial results?
Evonile Pharma's Board of Directors approved the unaudited financial results on Tuesday, November 03, 2026.
Which report was taken on record by Evonile Pharma's Board along with the results?
The Board took on record the Limited Review Report dated Tuesday, November 03, 2026, issued by the Statutory Auditors of the Company.
What was the duration of Evonile Pharma's Board meeting for results approval?
The Board meeting commenced at 06:06 P.M. (IST) and concluded at 06:26 P.M. (IST) on November 03, 2026.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.